A venture capital firm that historically focused on deep-tech and hardware is now expanding its scope to opportunities at the intersection of deep-tech and life sciences. The firm is currently investing from its second fund, sized at approximately USD $75M. The firm participates in Pre-Seed and Seed financing rounds, with typical allocations ranging from USD $500K to $2.5M. The firm prefers to lead or co-lead investment rounds and evaluates opportunities across Europe and the United States.
Within life sciences, the firm is open to digital health deep-tech companies but does not invest in application-only businesses. The firm does not pursue traditional therapeutics but will consider therapeutics that incorporate a strong data component, as well as multi-asset or platform-based technologies. The firm is also interested in diagnostics, non-invasive medical devices, surgical tools, and biomanufacturing. The firm focuses on companies at the pre-clinical and early development stages and is disease-agnostic.
The firm does not impose strict requirements on companies or management teams. The firm may consider taking a board seat or observer seat on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment